Inhibitors of the interaction between MDM2 and p53

Details for Australian Patent Application No. 2007228782 (hide)

Owner Janssen Pharmaceutica N.V.

Inventors Lacrampe, Jean Fernand Armand; Van Hijfte, Luc; Schoentjes, Bruno; Meyer, Christophe; Poncelet, Alain Philippe; Lardeau, Delphine Yvonne Raymonde

Agent Shelston IP

Pub. Number AU-B-2007228782

PCT Pub. Number WO2007/107543

Priority 06111531.7 22.03.06 EP; 60/784,780 22.03.06 US

Filing date 19 March 2007

Wipo publication date 27 September 2007

Acceptance publication date 6 September 2012

International Classifications

C07D 401/12 Heterocyclic compounds containing two or more hetero rings

A61K 31/4409 - only substituted in position 4, e.g. isoniazid, iproniazid

A61P 35/00 Antineoplastic agents

C07D 405/12 Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

6 November 2008 PCT application entered the National Phase

  PCT publication WO2007/107543 Priority application(s): WO2007/107543

6 September 2012 Application Accepted

  Published as AU-B-2007228782

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007228784-Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53

2007228778-Compounds which potentiate AMPA receptor and uses thereof in medicine